Loading clinical trials...

Intravenous Metoprolol in Septic Shock | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Intravenous Metoprolol in Septic Shock

EFFECT of INTRAVENOUS METOPROLOL TARTRATE on MORTALITY in PATIENTS with SEPTIC SHOCK DUE to VENTILATOR-ASSOCIATED PNEUMONIA Thesis

NCT06592547•Alexandria University

View on ClinicalTrials.gov

Summary

A RCT designed to assess the effect of giving intravenous beta-blockers in patients with septic shock after achieving hemodynamic stability. The principle of this study is to control heart rate allowing for better diastolic filling and thus better perfusion.

Detailed Description

A RCT, conducted at alexandria main university hospital, patients were divided into 2 groups, Control group which received the standard care for septic shock and metoprolol group which recieved intravenous metoprolol then patients were assessed for Blood pressure, heart rate, iv fluids needed, vasopressor doses and 28 days mortality

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The study population included adult patients (≥ 18 years) diagnosed with septic shock secondary to VAP with sinus tachycardia, from April 1, 2022, to April 31, 2023. Septic shock was defined according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). VAP was identified as per the guidelines provided by the American Thoracic Society and Infectious Diseases Society of America.

Exclusion Criteria

•Patients were excluded if they had contraindications to beta-blockers, had a history of heart failure, or had been receiving beta-blockers prior to the septic shock. Patients were also excluded if they developed complications from beta- blockers administration.

Locations (1)

Alexandria Main university hospital

Alexandria, Egypt

Key Dates

Start Date

April 1, 2022

Primary Completion Date

December 1, 2023

Completion Date

November 10, 2024

Last Updated

January 29, 2025

Enrollment

100

ACTUAL participants

Conditions

Septic ShockVentilator Acquired Pneumonia

Interventions

Intravenous metoprolol tartrate

DRUG

Standard Care (in control arm)

OTHER

Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock

NCT07179276

Sepsis - to Reduce Mortality in the Intensive Care UnitSeptic Shock

View study

RECRUITINGPHASE4

Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

NCT07383103

Septic Shock

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Intravenous Metoprolol in Septic Shock

Inclusion Criteria

Exclusion Criteria

Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock

Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

ARTICE® Real Data Collection & Observational Trial, Phase 4 Study

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

Early Methylene Blue in the Microhemodynamics of Septic Shock Patients

In Vivo Antibiotics Removal During Hemoadsorption Cartridges and Continuous Renal Replacement Therapy in the Intensive Care Unit